YMB completes Phase II cancer enrollment

YM BioSciences (LSE:YMB; TSE:YM.PR.B) completed enrollment in a North American Phase II study of its tesmilifene combined with mitoxantrone/prednisone to treat metastatic hormone refractory prostate cancer (HRPC). Tesmilifene is a small molecule chemopotentiator. ...